Trials / Withdrawn
WithdrawnNCT01198379
Aspirin in the Prevention of Cardiovascular Events in Hemodialysis Patients
Efficacy of Monitoring of Aspirin Responsiveness in the Prevention of Cardiovascular Events and Decrease in Bleeding Complications in Patients With End-Stage Kidney Disease Undergoing Hemodialysis
- Status
- Withdrawn
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The study is prospectively initiated to: (1) evaluate the alterations in platelet function to aspirin therapy and the prevalence of aspirin resistance in patients with chronic kidney disease undergoing hemodialysis, and (2) compare the incidence of vascular events (myocardial infarction, cardiac death, stroke, vascular access thrombosis, or revascularization procedure) and the safety profile among placebo-treated, aspirin-resistant and aspirin-sensitive patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | aspirin | aspirin 100 mg qd for 3 years |
| DRUG | Placebo |
Timeline
- Start date
- 2010-02-01
- Primary completion
- 2018-01-15
- Completion
- 2018-01-15
- First posted
- 2010-09-10
- Last updated
- 2019-01-17
Locations
1 site across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT01198379. Inclusion in this directory is not an endorsement.